Date:3/14/2010

renal disease. This is consistent with results from earlier clinical trials.(6,7) 'Diabetic nephropathy is a major management issue. Therefore it is important knowledge that fenofibrate provides benefit to these patients,' said Professor Michel Hermans of Cliniques Universitaires Saint-Luc, Brussels, Belgium and General Secretary of the R3i.

The study also confirmed that adding fenofibrate to simvastatin did not result in any excess risk of myopathy (muscle problems), venous thrombosis or pancreatitis. In fact, there were fewer all-cause and cardiovascular deaths in fenofibrate-treated patients than in patients treated with simvastatin alone.

R3i leads new research into atherogenic dyslipidemia in type 2 diabetes

Atherogenic dyslipidemia is common and the prevalence is markedly increasing as a result of the global epidemic of type 2 diabetes, obesity and metabolic syndrome.(8) So, in the U.S. about half of the high- risk patients beginning statin therapy may require additional treatment to lower their triglycerides and/or to raise their HDL-C.(9)

The
'/>"/>

SOURCE Residual Risk Reduction initiative (R3i) Copyright©2010 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5 6 7 8 9
Related biology technology :

1. Kensey Nash to Present at the Canaccord Adams Small-Cap Orthopedics Conference
2. Symmetry Medical to Present at Canaccord Adams Small-Cap Orthopedics Conference
3. Unmet Needs Provide Challenges and Opportunities for Rheumatoid Arthritis Drug Developers According to MedPredict Report
4. SyntheMed to Present at Canaccord Adams Small-Cap Orthopedics Conference
5. NuVasive to Present at Canaccord Adams Small-Cap Orthopedics Conference
6. Osteotech to Present at the Canaccord Adams Small-Cap Orthopedics Conference in San Francisco
7. C1-Esterase Inhibitor Concentrate Rapidly Relieves Abdominal and Facial Attacks in Patients with Hereditary Angioedema, According to Pivotal Study
8. As Billions in Blockbuster Drug Revenue Goes Off Patent, Life Sciences Companies are Challenged to Fundamentally Change Future R&D Strategies, According to New Deloitte Report
9. Anadys Pharmaceuticals to Present at the CanAccord Adams Hepatitis C Conference
10. Pharmasset to Present at the Canaccord Adams Hepatitis C Conference on Wednesday, April 9th
11. Sangamo BioSciences to Present at the Canaccord Adams Diabetes and Obesity Conference